Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29086728 | 0.75 | OPRM1 (0.40) | OPRM1OPRD1OPRK1KMT2AMEN1 | |
| SCHEMBL2296429 | 0.75 | TSHR (0.45) | ALDH1A1MAPK1TSHR | |
| SCHEMBL29456508 | 0.75 | CFB (0.38) | KMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL21491130 | 0.75 | CFB (0.38) | KMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL31472453 | 0.75 | CFB (0.38) | KMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL3709981 | 0.75 | IRAK4 (0.33) | HSP90AA1HSP90AB1 | |
| SCHEMBL21590170 | 0.75 | DRD2 (0.41) | — | |
| SCHEMBL19253667 | 0.73 | HPGD (0.35) | OPRM1OPRD1OPRK1KMT2AMEN1 | |
| SCHEMBL19253599 | 0.73 | HPGD (0.35) | OPRM1OPRD1OPRK1KMT2AMEN1 | |
| SCHEMBL16102421 | 0.72 | ALDH1A1 (0.33) | KMT2AMEN1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059942-A1 | Azetidinyl G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| EP-2215077-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | Prosidion Limited (GB) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009050522-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059942-A1 | Azetidinyl G-Protein Coupled Receptor Agonists | GPR119, GIPR, GPR39 | OPRM1 249/4885OPRD1 127/4885OPRK1 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.